MAP2K7 and cancer: In the clinic, MEK inhibitors are often used in combination with a B-Raf inhibitor, although multiple studies in different cancers have shown that they augment checkpoint inhibitor treatment as well [208,209,210,211,212], further highlighting their therapeutic potential.